Although cannabis is federally prohibited, a majority of U.S. states have implemented medical cannabis laws (MCLs). As more individuals consider the drug for medical treatment, they potentially substitute away from prescription drugs. Therefore, an MCL signals competitor entry. This paper exploits geographic and temporal variation in MCLs to examine the strategic response in direct-to-physician marketing by pharmaceutical firms as cannabis enters the market. Using office detailing records from 2014-2018 aggregated to the county level, we find weak evidence of a relatively small and delayed response in substitute prescription drug- and opioid-related detailing. While these effects on detailing dollars are more pronounced among smaller pharmaceutical firms, the magnitudes are economically small and likely muted at aggregate levels by the small percent of doctors that actively recommend cannabis for medical treatment.

中文翻译：

---

医用大麻法对医生药品营销的影响

尽管联邦政府禁止使用大麻，但美国大多数州已经实施了医用大麻法 (MCL)。随着越来越多的人考虑将这种药物用于医疗，他们可能会替代处方药。因此，MCL 标志着竞争对手进入。本文利用 MCL 的地理和时间变化来研究大麻进入市场时制药公司直接面向医生营销的战略反应。使用 2014 年至 2018 年汇总到县级的办公室详细记录，我们发现较弱的证据表明替代处方药和阿片类药物相关详细信息的响应相对较小且延迟。虽然这些对详细费用的影响在较小的制药公司中更为明显，